ArticleImmunity, inflammation and disease2026
Immune Cells as Mediators Between Gut Microbiota and Multiple Sclerosis: Insights From Mendelian Randomization.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Cells as Mediators Between Gut Microbiota and Multiple Sclerosis: Insights From Mendelian Randomization.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMultiple sclerosis (MS) is a neuroimmunological disorder marked by demyelination and neuronal damage, significantly impacting young individuals' health and quality of life. Recent studies suggest a pivotal role of the gut microbiota and immune system in MS development, though the precise mechanisms remain unclear.
methodsThis study utilizes Mendelian randomization (MR) to explore the causal relationships between gut microbiota, immune traits, and MS. We conducted MR analysis using genetic data from 18,340 participants for gut microbiota, 3757 individuals for immune traits, and 47,429 MS cases alongside 68,374 controls.
resultsOur results suggested six microbial taxa with nominally significant associations to MS, with two taxa (Roseburia and Ruminococcus2) exhibiting putative mediating trends through specific immune cell phenotypes (CD28 on CD28
conclusionThese nominally significant exploratory findings provide hypothesis-generating clues that immune cell activation, particularly in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.